Clinical Trials for Mesothelioma Patient tumors—A Study to Find the Best Dose of SU011248: Outcome Measures

Read about the outcome measures for a current clinical trial about the use of SU011248 for patients with mesothelioma tumors. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Primary Outcome Measures:

• To determine maximally tolerated dose of SU011248 (dosed continuously or on a 2/1 Schedule) when given in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin. [ Time Frame: From screening until at least 28 days beyond discontinuation of study treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

• To evaluate the pharmacokinetics of SU011248 and pemetrexed, SU011248, pemetrexed and cisplatin and SU011248, pemetrexed and carboplatin when these drugs are co-administered. [ Time Frame: From screening until disease progression or discontinuation of the study ] [ Designated as safety issue: No ]
• To preliminarily assess the antitumor activity of SU011248 and pemetrexed in non-small cell lung cancer patients. [ Time Frame: From screening until disease progression or discontinuation of the study ] [ Designated as safety issue: No ]
• To preliminarily assess the antitumor activity of SU011248, pemetrexed and cisplatin and SU011248, pemetrexed and carboplatin in patients with non-small cell lung cancer or advanced unresectable mesothelioma. [ Time Frame: From screening until disease progression or discontinuation of the study ] [ Designated as safety issue: No ]

Estimated Enrollment: 100

Study Start Date: November 2006

Estimated Study Completion Date: May 2009

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.